Neuronetics Inc (NASDAQ:STIM) has received an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $34.50.
A number of research firms have recently commented on STIM. Zacks Investment Research raised Neuronetics from a “hold” rating to a “buy” rating and set a $29.00 price target for the company in a report on Saturday. BTIG Research reaffirmed a “buy” rating and issued a $33.00 price target on shares of Neuronetics in a report on Wednesday. Canaccord Genuity began coverage on Neuronetics in a report on Tuesday, July 24th. They issued a “buy” rating and a $33.00 price target for the company. Piper Jaffray Companies began coverage on Neuronetics in a report on Monday, July 23rd. They issued an “overweight” rating for the company. Finally, JMP Securities began coverage on Neuronetics in a report on Monday, July 23rd. They issued a “$26.02” rating and a $36.00 price target for the company.
NASDAQ:STIM traded down $0.70 during trading hours on Friday, reaching $24.75. The stock had a trading volume of 78,786 shares, compared to its average volume of 103,428. The company has a debt-to-equity ratio of 0.33, a current ratio of 7.63 and a quick ratio of 1.59. Neuronetics has a 12-month low of $20.70 and a 12-month high of $39.39.
Neuronetics (NASDAQ:STIM) last released its earnings results on Tuesday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.11. The firm had revenue of $13.74 million during the quarter, compared to analysts’ expectations of $12.68 million. On average, equities analysts predict that Neuronetics will post -1.98 EPS for the current year.
Large investors have recently bought and sold shares of the stock. American International Group Inc. bought a new stake in Neuronetics during the third quarter valued at $136,000. Victory Capital Management Inc. bought a new stake in Neuronetics during the second quarter valued at $133,000. Pier Capital LLC bought a new stake in Neuronetics during the second quarter valued at $186,000. Engineers Gate Manager LP bought a new stake in Neuronetics during the third quarter valued at $284,000. Finally, Granahan Investment Management Inc. MA bought a new stake in Neuronetics during the second quarter valued at $266,000. 60.76% of the stock is owned by institutional investors.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Read More: Earnings Per Share (EPS)
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.